The disconnect between great news and a compressed IPIX
The disconnect between great news and a compressed IPIX share price (SP) is obvious to anyone who has been paying attention. I spelled this out in detail in post #63656 that is a sticky post above.
As I have mentioned numerous times the advancement of the science is the ONLY thing that matters at this point IMO. IPIX investors are part owners of what very well could be THE BEST AND MOST EFFECTIVE TREATMENT FOR COVID-19. Some will call this “drinking the Kool-Aid” which could be the line of thinking of a short term stock trader, an impatient investor or possibly a paid poster trying to divert great news of IPIX science advancement by highlighting the criminally controlled SP.
Many Longs on this board have tried to educate the masses on the how, what and who in regards to the criminal manipulation of IPIX’s SP. Naked Short Selling is one of the tools that the criminals use to maintain control in the short term as they continue to compress SP. However, if the criminals target a company that has “the goods” that successfully make it to market, the criminals are screwed. Again, anyone who has been paying attention knows that as milestones are met that the criminal control over IPIX SP will loosen. In the short term SP DOES NOT MATTER. IPIX SP will sharply go up as the following key milestones are met:
Non-dilutive funding in the form of government grants and or Pharmaceutical partnerships.
Human lung testing results.
Successful COVID-19 specific human trial completion.
Brilacidin NDA approval for COVID-19 which will in turn greatly accelerate B-OM and B-IBD Oral approvals creating enormous revenue and royalties.
Eventual IPIX Up-listing off criminally controlled OTX.
Advancement of Kevetrin science.
Unwinding of criminal NSS covering which will have a slingshot upward effect on SP.
Eventual sale of IPIX a few years down the road.
Each of the above milestones will drive IPIX SP up in multiple dollar chunks REGARDLESS of what the criminals/NR do. IPIX is on track for all of the above to take place. The criminals need actual shares to cover their naked position and will attempt to persuade investors to start their exit strategies in the beginning of the above milestones. Selling into these initial milestones will be a long term mistake IMO. Each milestone above will add multiple dollars to IPIX’s share price and Brilacidin will save many thousands of lives.
15
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...
Continue Reading
Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...
Continue Reading
Revving up efficiency in healthcare usually sounds like pie-in-the-sky talk, but every now and again, an innovation comes along that really stirs the pot. Enter Dyania Health's Synapsis AI, a clinical reasoning AI, teaming with NVIDIA's robust computing infrastructure. They're setting out to make sense of massive amounts of patient data, securely tucked behind a...
Continue Reading
Shockwaves from D-Wave's Earnings Call August wasn't exactly a banner month for D-Wave Quantum, Inc. as their stock went down like a lead balloon following a lackluster earnings report. If you've ever had any skin in the game, you'd know a 9.5% drop isn't just peanuts—it's the equivalent of watching your prized racehorse stumble at the first hurdle. The financials spoke...
Continue Reading
Port Strategy and Financial Implications Terminales Portuarios Euroandinos Paita S.A., nestled in the Peruvian transport sector, has been tight-rope walking through its debt landscape. Announcing a successful consent solicitation on November 13, 2026, they've taken a significant step towards reconfiguring their long-term financing game. This puppet show of paperwork...
Continue Reading
A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...
Continue Reading
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
Downturn Despite Strategic Restructuring Today, we're diving into Fly-E Group, Inc. (NASDAQ:FLYE) and the latest shakeup in their financials—spoiler alert, it's riding a downward slope. Quarter two of fiscal 2027 didn't exactly shine a light on profitability. Net revenues slid, dropping to $2.6 million this quarter, down from $3.9 million the previous year. Tack that up...
Continue Reading
Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...
Continue Reading
Big Moves in the Tech Jungle: FiEE's Comeback Let's chew the fat on FiEE, Inc., a company that's left its hardware-heavy past in the dust and grabbed the bull by the horns with fresh, AI-driven brand tech solutions. We're talking a whopping 382.1% revenue increase. Now, that's not chump change. From barely scraping $2 million last year to raking in $9.6 million just for...
Continue Reading
Top 5 Most Recently Viewed Articles
Cresilon Partners with McCarthy Vet to Distribute VETIGEL Cresilon Inc., an innovative biotechnology firm known for its advanced hemostatic products, has announced a transformative agreement with McCarthy Vet. This collaboration marks a significant step forward as it allows for the distribution of VETIGEL, a groundbreaking hemostatic gel, directly to veterinary surgeons....
Continue Reading
Absci Corporation's Upcoming Financial Reports Absci Corporation (Nasdaq: ABSI), recognized as a pioneer in data-driven generative AI for drug discovery, is gearing up to release important business updates along with financial results for the first quarter of 2025. This report is scheduled to be unveiled subsequent to market close. Key Highlights of the Upcoming Report...
Continue Reading
Borregaard ASA's Second Quarter Results Announcement Borregaard ASA, a renowned name in biochemistry, is set to present its Q2 2025 results. This event will take place on Wednesday, coinciding with July 16, 2025, at 07:00 CEST. As anticipated, a comprehensive stock exchange announcement will follow shortly thereafter. What to Expect from the Presentation The presentation...
Continue Reading
JP Conte's Bet on Brazilian Waste-to-Energy Giant Here's the scoop, folks. Lupine Crest Capital, helmed by none other than JP Conte, just doubled down on their investment in Brazil. This isn't some negligible penny-ante increase, but a hefty infusion of R$70 million—think roughly $14 million in USD—into Orizon Valorização de Resíduos S.A., the notable...
Continue Reading
Hedge funds adjusted their playbooks back then in 2023, net selling equities amid a flurry of options expiry and index rebalancing. The desks were abuzz as they noted slight selling pressure from these funds, yet after the dust settled on that chaotic week, buying picked up noticeably—especially Thursday when it seemed traders found some footing again. Macro Products...
Continue Reading